ACME Laboratories (DHA:ACMELAB) Total Long-Term Assets: BDT33,313 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
85 GF Score
Price BDT83.30
GF Value BDT126.77
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories Total Long-Term Assets?

ACME Laboratories DHA:ACMELAB -0.36% 85 Total Long-Term Assets is BDT33,313 Mil as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT126.77 (Possible Value Trap). The stock has 7 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. ACME Laboratories's Total Long-Term Assets for the quarter that ended in Mar. 2026 was BDT33,313 Mil.

ACME Laboratories Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories Total Long-Term Assets Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only 24,712.74 25,135.91 25,631.87 29,274.16 31,759.35

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32,465.14 32,636.16 33,450.06 33,143.90 33,313.13
DHA:ACMELAB
85GF Score
ACME Laboratories Ltd DHA:ACMELAB
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of BDT33,313 Mil mean?
ACME Laboratories (DHA:ACMELAB) has a Total Long-Term Assets of BDT33,313 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on ACME Laboratories and its competitors.
Is ACME Laboratories' Total Long-Term Assets too high?
ACME Laboratories' current Total Long-Term Assets is BDT33,313 Mil. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Total Long-Term Assets compare to ZTS and UTHR?
ACME Laboratories' Total Long-Term Assets of BDT33,313 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on ACME Laboratories and its competitors. ACME Laboratories's current Total Long-Term Assets is BDT33,313 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT126.77, compared to a current price of BDT83.30 — trading 34.3% below its estimated fair value. The current Total Long-Term Assets is BDT33,313 Mil. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Total Long-Term Assets is BDT33,313 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT83.30 is trading 34.3% below its estimated GF Value™ of BDT126.77. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • Total Long-Term Assets: BDT33,313 Mil
  • GF Value™: BDT126.77 vs. price of BDT83.30 (34.3% below fair value)
  • GF Score™: 85/100 with 7 warning signs

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score

Get the complete analysis for DHA:ACMELAB

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT83.30
Price
BDT126.77
GF Value